Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cerevel Therapeutics Holdings - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CERE
Nasdaq
8731
https://www.cerevel.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cerevel Therapeutics Holdings
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
- Dec 7th, 2023 3:04 pm
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
- Dec 6th, 2023 9:30 pm
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
- Nov 29th, 2023 11:30 am
Cerevel Therapeutics to Present at Upcoming Investor Conferences
- Nov 8th, 2023 11:30 am
Cerevel Therapeutics Holdings Inc (CERE) Reports Q3 2023 Financial Results
- Nov 1st, 2023 1:14 pm
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
- Nov 1st, 2023 10:30 am
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
- Oct 13th, 2023 10:30 am
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
- Oct 12th, 2023 2:45 am
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
- Oct 11th, 2023 8:01 pm
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
- Aug 29th, 2023 10:30 am
Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay Attention
- Aug 11th, 2023 6:21 pm
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
- Aug 2nd, 2023 10:30 am
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
- Jul 5th, 2023 10:30 am
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
- Jun 15th, 2023 10:30 am
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
- May 10th, 2023 10:30 am
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
- May 3rd, 2023 10:30 am
Billionaire Joseph Edelman Snaps Up These 2 Biotech Stocks — Here’s Why You Should Follow
- Apr 26th, 2023 2:01 pm
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
- Apr 26th, 2023 10:30 am
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023
- Apr 11th, 2023 10:30 am
Scroll